| McDermott, Michael |
NCT03671889: ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease |
|
|
| Recruiting | N/A | 150 | US | Blood Brain Barrier (BBB) Disruption, ExAblate Neuro | InSightec | Alzheimer Disease | 12/25 | 12/25 | | |
NCT05756985: Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue |
|
|
| Recruiting | N/A | 120 | US | Specimen Collection | Baptist Health South Florida, Miami Cancer Institute, Nico Corporation | Glioblastoma, Glioblastoma Multiforme, Gliosarcoma | 01/27 | 01/29 | | |
| Active, not recruiting | N/A | 1339 | Europe, Canada, US | No intervention | Takeda, Takeda Development Center Americas, Inc. | Hypoparathyroidism | 11/34 | 11/34 | | |
| Rezai, Ali |
NCT05603312: A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants |
|
|
| Completed | 1/2 | 14 | US | AAV-GAD Dose 1, AAV-GAD Dose 2, Sham Surgery | MeiraGTx, LLC | Parkinson Disease | 09/24 | 09/24 | | |
NCT05469009: Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy |
|
|
| Recruiting | 1 | 15 | US | Aducanumab, Aduhelm, Exablate Model 4000 Type 2, Focused Ultrasound, Lecanemab, Leqembi | Ali Rezai, InSightec | Mild Cognitive Impairment, Alzheimer Disease 1 | 07/29 | 07/29 | | |
DBS OUD, NCT03950492: Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder |
|
|
| Active, not recruiting | N/A | 4 | US | Deep Brain Simulator | West Virginia University, National Institute on Drug Abuse (NIDA), Medtronic | Opioid-Related Disorders | 12/22 | 12/26 | | |
NCT06612788: Exablate for LIFU Neuromodulation in Patients with Opioid Use Disorder (OUD) |
|
|
| Active, not recruiting | N/A | 5 | US | Exablate Model 4000 Type 2.0/2.1 | West Virginia University, National Institute on Drug Abuse (NIDA), InSightec | Opioid Use Disorder | 07/24 | 04/25 | | |
NCT04197921: Exablate for LIFU Neuromodulation in Patients with Opioid Use Disorder (OUD) And/or Other Substance Use Disorders (SUDs) |
|
|
| Recruiting | N/A | 29 | US | Exablate Model 4000 Type 2.0/2.1 | InSightec | Opioid-use Disorder, Substance Use Disorders | 12/25 | 12/26 | | |
NCT03671889: ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease |
|
|
| Recruiting | N/A | 150 | US | Blood Brain Barrier (BBB) Disruption, ExAblate Neuro | InSightec | Alzheimer Disease | 12/25 | 12/25 | | |
| Cifarelli, Christopher P |
| Active, not recruiting | 3 | 314 | Europe, Canada, US, RoW | Standard surgery, Intraoperative radiotherapy, IORT, Radiochemotherapy, Temozolomide | Universitätsmedizin Mannheim, Carl Zeiss Meditec AG, University of California, Los Angeles | Glioblastoma | 06/24 | 06/26 | | |
LIBERATE, NCT05383872: Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with GlioBlastoma Brain Tumors |
|
|
| Recruiting | N/A | 57 | Canada, US | Focused Ultrasound (Exablate Model 4000) | InSightec | Glioblastoma, Glioma, Liquid Biopsy | 12/24 | 03/25 | | |
| Woodworth, Graeme F |
NCT05317858: Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets |
|
|
| Recruiting | 3 | 20 | Canada, US, RoW | Blood Brain Barrier Disruption - Oncology, Exablate BBBD, Pembrolizumab | InSightec | Brain Tumor | 06/24 | 12/24 | | |
NCT04417088: Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy |
|
|
| Active, not recruiting | 1/2 | 30 | US | Carboplatin, Exablate BBBD, Exablate Neuro | InSightec | Recurrent Glioblastoma | 12/23 | 07/24 | | |
NCT03551249: Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption |
|
|
| Completed | N/A | 20 | US | Focused ultrasound (FUS), ExAblate, Type 2 | InSightec | Glioma, Glioblastoma | 12/23 | 12/23 | | |
LIBERATE, NCT05383872: Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with GlioBlastoma Brain Tumors |
|
|
| Recruiting | N/A | 57 | Canada, US | Focused Ultrasound (Exablate Model 4000) | InSightec | Glioblastoma, Glioma, Liquid Biopsy | 12/24 | 03/25 | | |
| Everson, Kiley |
LIBERATE, NCT05383872: Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with GlioBlastoma Brain Tumors |
|
|
| Recruiting | N/A | 57 | Canada, US | Focused Ultrasound (Exablate Model 4000) | InSightec | Glioblastoma, Glioma, Liquid Biopsy | 12/24 | 03/25 | | |
NCT03671889: ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease |
|
|
| Recruiting | N/A | 150 | US | Blood Brain Barrier (BBB) Disruption, ExAblate Neuro | InSightec | Alzheimer Disease | 12/25 | 12/25 | | |
| Klontz, Charlie |
NCT05317858: Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets |
|
|
| Recruiting | 3 | 20 | Canada, US, RoW | Blood Brain Barrier Disruption - Oncology, Exablate BBBD, Pembrolizumab | InSightec | Brain Tumor | 06/24 | 12/24 | | |
LIBERATE, NCT05383872: Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with GlioBlastoma Brain Tumors |
|
|
| Recruiting | N/A | 57 | Canada, US | Focused Ultrasound (Exablate Model 4000) | InSightec | Glioblastoma, Glioma, Liquid Biopsy | 12/24 | 03/25 | | |
| Torroella, Jordina Rincon |
LIBERATE, NCT05383872: Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with GlioBlastoma Brain Tumors |
|
|
| Recruiting | N/A | 57 | Canada, US | Focused Ultrasound (Exablate Model 4000) | InSightec | Glioblastoma, Glioma, Liquid Biopsy | 12/24 | 03/25 | | |
| Patel, Bhumi |
NCT03671889: ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease |
|
|
| Recruiting | N/A | 150 | US | Blood Brain Barrier (BBB) Disruption, ExAblate Neuro | InSightec | Alzheimer Disease | 12/25 | 12/25 | | |
